StockTipsArenaBeta

GlaxoSmithKline Pharmaceuticals Share price target & analyst calls

Sector:Pharmaceuticals & Biotechnology
₹2,464.4-31.00 (-1.24%)
As of 21 Oct 2026

Only one active 1–3 month target

The short-term call is BUY

₹3,70050.1% above today's price

GlaxoSmithKline Pharmaceuticals has one active 1–3 month share price target: ₹3,700 from Rakesh Bansal (19 Aug 2026). One target is a single view, not a consensus.

1
1 BUY · 0 SELL, all horizons
1
with an active 1–3M target
N/A
7 of 10 closed calls needed
8
all horizons, open and closed
Watch GLAXO for new buy/sell callsGet alertsSee 44 Pharmaceuticals & Biotechnology sector analyst picks

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

All tips (8)

SELLTarget₹2,600
ISbyICICI SecuritiesTarget hit
1 Year* · 14 May 2025 · entry ₹2,878.8 · via Institutional / Brokerage Researchexit ₹2,600
BUYTarget₹3,700
RBbyRakesh Bansal+50.1% to target
1–3 Months · 4 wk left · 19 Aug 2026 · entry ₹2,982.5 · via Zee Business (Live)P&L -17.4%
BUYTarget₹2,975
ABbyAkshay Bhagwat, JM FinancialTarget hit
1–2 Weeks* · 18 Aug 2026 · entry ₹2,877.3 · via ET Now (Live)exit ₹2,975
BUYTarget₹2,650
PGbyPrakash GabaTarget hit
1–2 Weeks* · 28 Jul 2026 · entry ₹2,615 · via CNBC Awaaz.exit ₹2,650
BUYTarget₹3,062
ICbyIDBI CapitalStop-loss hit
1–2 Weeks* · 23 Sept 2026 · entry ₹2,908 · via IDBI Capital Research Calls Telegramexit ₹2,831
BUYTarget₹3,200
KBbyKunal BothraStop-loss hit
1–2 Weeks* · 27 Aug 2026 · entry ₹3,103.2 · via ET Now (Live)exit ₹3,050
BUYTarget₹2,725
KBbyKush BohraStop-loss hit
1–2 Weeks* · 23 Jul 2026 · entry ₹2,552.8 · via NDTV Profitexit ₹2,470
BUYTarget₹2,700
ICbyIDBI CapitalExpired
1–2 Weeks* · 21 Jul 2026 · entry ₹2,502 · via IDBI Capital Research Calls Telegramexit ₹2,664.9

* Horizon not stated by the source; assumed from how far the target is from the entry price.

Compare Pharmaceuticals & Biotechnology targets

Most-covered stocks in the sector · average 1-year target

See all Pharmaceuticals & Biotechnology analyst picks